thiazoles has been researched along with Heritable Pulmonary Arterial Hypertension in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allawzi, AM; Choudhary, G; Clements, RT; Comhair, SA; Erzurum, SC; Jhun, BS; Kue, NR; Landi, AK; Mancini, TJ; O-Uchi, J; Terentyev, D; Vang, A | 1 |
| Kim, DH; Kim, JC; Kim, SH; Kwan, J; Park, KS; Shin, SH; Woo, SI; Yi, HG | 1 |
| Hao, P; Li, R; Li, X; Li, Y; Liu, G; Sun, Y; Tang, X; Xu, J | 1 |
| Humbert, M; Jardim, C; Souza, R | 1 |
| Bergot, E; Godinas, L; Guignabert, C; Humbert, M; Montani, D; Perros, F; Seferian, A; Sibille, Y | 1 |
| Li, JY; Qiu, ZY; Xu, W | 1 |
| Dumitrescu, D; Erdmann, E; Gerhardt, F; Rosenkranz, S; Seck, C; ten Freyhaus, H | 1 |
| Ghio, S; Orlandi, EM; Pazzano, AS; Rocca, B | 1 |
| Hayashi, H; Katoh, H; Ohnishi, K; Sano, M; Saotome, M; Satoh, H; Urushida, T | 1 |
2 review(s) available for thiazoles and Heritable Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?
Topics: Apoptosis; Benzamides; Cell Proliferation; Dasatinib; Endothelial Cells; ErbB Receptors; Familial Primary Pulmonary Hypertension; Fibroblast Growth Factor 2; Fibroblasts; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Niacinamide; Phenylurea Compounds; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pulmonary Circulation; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sorafenib; src-Family Kinases; Thiazoles; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Large granular lymphocytosis during dasatinib therapy.
Topics: Antineoplastic Agents; Clone Cells; Colitis; Dasatinib; Familial Primary Pulmonary Hypertension; Humans; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytosis; Pleural Effusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; T-Lymphocytes, Cytotoxic; Thiazoles; Thrombocytopenia | 2014 |
8 other study(ies) available for thiazoles and Heritable Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
Activation of Anoctamin-1 Limits Pulmonary Endothelial Cell Proliferation via p38-Mitogen-activated Protein Kinase-Dependent Apoptosis.
Topics: Animals; Anoctamin-1; Apoptosis; Benzamides; Case-Control Studies; Cell Hypoxia; Cell Proliferation; Cells, Cultured; Endothelial Cells; Familial Primary Pulmonary Hypertension; Humans; Lung; Mitochondria; Neoplasm Proteins; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Rats; Reactive Oxygen Species; Signal Transduction; Thiazoles | 2018 |
Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib.
Topics: Adult; Dasatinib; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
PPARĪ“ agonist GW501516 inhibits PDGF-stimulated pulmonary arterial smooth muscle cell function related to pathological vascular remodeling.
Topics: Cell Differentiation; Cell Movement; Cell Proliferation; Chemokine CCL2; Collagen; Familial Primary Pulmonary Hypertension; Gene Expression Regulation; Humans; Hypertension, Pulmonary; Molecular Targeted Therapy; Myocytes, Smooth Muscle; Neovascularization, Pathologic; Platelet-Derived Growth Factor; PPAR delta; Pulmonary Artery; Thiazoles; Transcriptional Activation; Up-Regulation | 2013 |
Idiopathic pulmonary arterial hypertension.
Topics: Aminorex; Antihypertensive Agents; Appetite Depressants; Bosentan; Dasatinib; Epoprostenol; Familial Primary Pulmonary Hypertension; Fenfluramine; Genetic Predisposition to Disease; Humans; Hypertension, Pulmonary; Iloprost; Phenylpropionates; Piperazines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridazines; Pyrimidines; Risk Factors; Sildenafil Citrate; Sulfonamides; Sulfones; Thiazoles; Vasodilator Agents | 2013 |
Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Blood Pressure; Dasatinib; Familial Primary Pulmonary Hypertension; Hemodynamics; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pulmonary Medicine; Pyrimidines; Thiazoles; Treatment Outcome; Ventricular Dysfunction, Right | 2011 |
Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Dasatinib; Dose-Response Relationship, Drug; Electrocardiography; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Pyrimidines; Remission, Spontaneous; Thiazoles; Time Factors | 2012 |
Dasatinib: pulmonary arterial hypertension. French data.
Topics: Antineoplastic Agents; Dasatinib; Familial Primary Pulmonary Hypertension; France; Humans; Hypertension, Pulmonary; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2011 |
Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-.
Topics: Dasatinib; Echocardiography; Electrocardiography; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Sildenafil Citrate; Sulfones; Thiazoles; Treatment Outcome; Vasodilator Agents; Withholding Treatment | 2012 |